Business Wire

Summit Health Announces Internalization of Genomic Testing Cooperative State-of-The-Art Next Generation Sequencing DNA and RNA Profiling Tests for Tissue and Liquid Biopsy of ...

LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)--Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today ...

Researchers show benefit of ultra-deep RNA sequencing in Mendelian disorder diagnostics

RNA sequencing (RNA-seq) is a powerful tool in diagnosing Mendelian disorders, but the optimized sequencing depth for this technology has not yet ...
Precision Medicine Online

Genetic Testing Challenges in Precision Medicine: DNA, RNA Sequencing Picks Up Intronic NF1 Variant

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...
Morningstar

Molecular Instruments® Continues RNA Imaging Leadership with Next-Generation miRNA/siRNA Detection and Clinical-Grade Ready-to-Use Kits

Both HCR™ Gold and HCR™ Pro now incorporate next-generation HCR™ HiFi architecture, enabling robust detection of small RNAs such as miRNA and siRNA with built-in automatic background suppression, ...
Healio

Most patients with advanced cancer do not undergo next-generation sequencing testing

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
ascopubs.org

Adjuvant abemaciclib outcomes in routine clinical practice (experience of several Moscow centers).

Factors impacting treatment with abemaciclib + endocrine therapy in high risk early-stage HR+/HER2- breast cancer patients. Integration of next-generation RNA sequencing-based MammaPrint and BluePrint ...
ascopubs.org

Ethnic differences in nonalcoholic fatty liver disease (NAFLD) among women with early-stage breast cancer receiving endocrine therapy.

Integration of next-generation RNA sequencing-based MammaPrint and BluePrint analysis in clinical decision making: Performance evaluation in the first 1095 cases. This is an ASCO Meeting Abstract from ...